Form 4: Bio-Techne Director John L. Higgins Reports Acquisition of Common Stock and Stock Options
SEC Form 4
Director John L. Higgins reports acquiring 1,462 shares of Bio-Techne common stock and 3,511 stock options, while also disposing of an unspecified amount of common stock.
Summary
- On October 24, 2024, John L. Higgins, a director of Bio-Techne Corp, reported acquiring 1,462 shares of common stock at $0 and 3,511 stock options.
- Higgins also disposed of an unspecified amount of common stock.
- Following these transactions, Higgins beneficially owns 48,196 shares of common stock.
- Higgins also holds various stock options with exercise prices ranging from $21.84 to $128.81, expiring between 2025 and 2034.
- The newly acquired options vest on the earlier of October 24, 2025, or the date of Bio-Techne's 2025 annual meeting of shareholders.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While the acquisition of stock options is generally positive, the disposal of common stock introduces uncertainty. The overall impact depends on the size of the disposal, which is not specified.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The disposal of an unspecified amount of common stock by the director could be interpreted negatively by investors.
Risks
- The Form 4 filing itself doesn't inherently present risks, but the market's interpretation of the director's transactions could lead to price volatility.
- The vesting of the new options is tied to the annual shareholder meeting, which could introduce uncertainty depending on the meeting's outcome.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Comparing the option grants to similar companies in the biotechnology and life sciences sector would provide context on whether the size and terms of these grants are standard.
- Companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies could be used as benchmarks for executive compensation and stock ownership.
Stakeholder Impact
- Shareholders may react to the reported transactions, potentially influencing the stock price.
- The transactions could affect employee morale if perceived as a sign of confidence or lack thereof by a key executive.
Key Dates
| Date | Description |
|---|---|
| 10/29/2016 | Date of exercisable stock options with an expiration date of 10/28/2025 and an exercise price of $21.84. |
| 10/26/2017 | Date of exercisable stock options with an expiration date of 10/26/2026 and an exercise price of $25.3. |
| 10/25/2018 | Date of exercisable stock options with an expiration date of 10/27/2027 and an exercise price of $31.26. |
| 10/24/2019 | Date of exercisable stock options with an expiration date of 10/25/2028 and an exercise price of $44.96. |
| 10/24/2020 | Date of exercisable stock options with an expiration date of 10/24/2029 and an exercise price of $50.41. |
| 10/28/2021 | Date of exercisable stock options with an expiration date of 10/29/2030 and an exercise price of $63.92. |
| 10/27/2022 | Date of exercisable stock options with an expiration date of 10/28/2031 and an exercise price of $128.81. |
| 10/26/2023 | Date of exercisable stock options with an expiration date of 10/27/2032 and an exercise price of $73.94. |
| 10/24/2024 | Date of transaction: acquisition of common stock and stock options. Date of exercisable stock options with an expiration date of 10/26/2033 and an exercise price of $61.51. Date of exercisable stock options with an expiration date of 10/24/2034 and an exercise price of $68.37. |
| 10/28/2024 | Date of filing. |
| 10/24/2025 | Date the option vests, or the date of Bio-Techne's 2025 annual meeting of shareholders, whichever is earlier. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.